ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Nevada » Hematology Oncology

Top Hematology Oncology Prescribers in Nevada

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
GRZEGORZ OBARA MD

Hematology Oncology

2,887

$774K

214
169 are 65+

16%
patients receiving schedule two controlled substances

Avg: 13%

22%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$268
Average prescription price

Avg: $449

RUSSELL GOLLARD M.D.

Hematology Oncology

2,306

$987K

310
273 are 65+

15%
patients receiving schedule two controlled substances

Avg: 13%

13%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$428
Average prescription price

Avg: $449

RUPESH PARIKH MD

Hematology Oncology

2,074

$634K

304
266 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

11%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 17%

$306
Average prescription price

Avg: $449

EMELINA QUISUMBING M.D.

Hematology Oncology

2,036

$705K

295
208 are 65+

12%
patients receiving schedule two controlled substances

Avg: 13%

14%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$346
Average prescription price

Avg: $449

GILBERT NYAMUSWA M.D.

Hematology Oncology

2,030

$1.01M

354
316 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$495
Average prescription price

Avg: $449

ANN WIERMAN MD, FACP

Hematology Oncology

1,917

$377K

281
241 are 65+

11%
patients receiving schedule two controlled substances

Avg: 13%

19%
patients receiving schedule three controlled substances

Avg: 11%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 17%

$197
Average prescription price

Avg: $449

ANURADHA THUMMALA MD

Hematology Oncology

1,746

$273K

231
191 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 17%

$157
Average prescription price

Avg: $449

HYO-JONG PARK M.D.

Hematology Oncology

1,632

$1.17M

313
255 are 65+

18%
patients receiving schedule two controlled substances

Avg: 13%

8%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 17%

$717
Average prescription price

Avg: $449

DHAN KAUSHAL M.D.

Hematology Oncology

1,575

$779K

348
307 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

11%
patients receiving schedule three controlled substances

Avg: 11%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$495
Average prescription price

Avg: $449

RAMALINGAM RATNASABAPATHY M.D.

Hematology Oncology

1,562

$981K

247
222 are 65+

13%
patients receiving schedule two controlled substances

Avg: 13%

7%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 17%

$628
Average prescription price

Avg: $449

MUHAMMAD GHANI M.D.

Hematology Oncology

1,554

$936K

318
267 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$602
Average prescription price

Avg: $449

PAUL MICHAEL MD

Hematology Oncology

1,499

$688K

181
141 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

14%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 17%

$459
Average prescription price

Avg: $449

BRIAN VICUNA MD

Hematology Oncology

1,382

$280K

241
204 are 65+

24%
patients receiving schedule two controlled substances

Avg: 13%

14%
patients receiving schedule three controlled substances

Avg: 11%

8%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 17%

$202
Average prescription price

Avg: $449

JOHN ELLERTON MD, CM

Hematology Oncology

1,337

$1.01M

140
110 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

18%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 17%

$755
Average prescription price

Avg: $449

JAMES SANCHEZ MD

Hematology Oncology

1,322

$775K

166
143 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

14%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 17%

$586
Average prescription price

Avg: $449

CLARK JEAN MD

Hematology Oncology

1,299

$628K

209
160 are 65+

19%
patients receiving schedule two controlled substances

Avg: 13%

16%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$483
Average prescription price

Avg: $449

NICHOLAS VOGELZANG MD

Hematology Oncology

1,200

$1.22M

172
154 are 65+

16%
patients receiving schedule two controlled substances

Avg: 13%

14%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

31%
prescriptions for brand name drugs

Avg: 17%

$1014
Average prescription price

Avg: $449

EDWIN KINGSLEY MD

Hematology Oncology

1,196

$557K

164
143 are 65+

13%
patients receiving schedule two controlled substances

Avg: 13%

15%
patients receiving schedule three controlled substances

Avg: 11%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$466
Average prescription price

Avg: $449

HEATHER ALLEN MD

Hematology Oncology

1,169

$308K

179
146 are 65+

7%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 17%

$263
Average prescription price

Avg: $449

EDGARDO FAYLONA M.D.

Hematology Oncology

1,052

$449K

215
185 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 17%

$427
Average prescription price

Avg: $449

JOHN KELLY MD

Hematology Oncology

1,034

$1.09M

189
162 are 65+

15%
patients receiving schedule two controlled substances

Avg: 13%

9%
patients receiving schedule three controlled substances

Avg: 11%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$1051
Average prescription price

Avg: $449

AARON BOWMAN MD

Hematology Oncology

982

$370K

126
106 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 17%

$377
Average prescription price

Avg: $449

KHOI DAO MD

Hematology Oncology

960

$395K

224
196 are 65+

11%
patients receiving schedule two controlled substances

Avg: 13%

15%
patients receiving schedule three controlled substances

Avg: 11%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$411
Average prescription price

Avg: $449

HOLAVANAHALL PRASAD MD

Hematology Oncology

917

$301K

163
132 are 65+

11%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$328
Average prescription price

Avg: $449

MARY ANN ALLISON

Hematology Oncology

839

$103K

195
174 are 65+

6%
patients receiving schedule two controlled substances

Avg: 13%

0%
patients receiving schedule three controlled substances

Avg: 11%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 17%

$123
Average prescription price

Avg: $449

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank